A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression

Authors: Peter Nägele, Ben Julian A. Palanca, Britt M. Gott, Frank Brown, Linda Barnes, Thomas Nguyen, Willa Xiong, Naji C. Salloum, Gemma Espejo, Christina N. Lessov‐Schlaggar, Nisha Jain, Wayland W.L. Cheng, Helga Komen, Branden E. Yee, Jacob Bolzenius, Alvin M. Janski, Robert D. Gibbons, Charles F. Zorumski, Charles R. Conway - Science Translational Medicine 2021 cited by 129

< 0.001). These results suggest that 25% nitrous oxide has comparable efficacy to 50% nitrous oxide in improving TRMD but with a markedly lower rate of adverse effects.